Literature DB >> 21194598

Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists.

Bradley S Miller1, Aseem R Shukla.   

Abstract

BACKGROUND: Long-acting forms of gonadotropin-releasing hormone (GnRH) receptor agonists are commonly used for the treatment of central precocious puberty (CPP). Sterile abscess formation has been reported as a complication of leuprolide acetate, but not histrelin acetate.
OBJECTIVE: The aim of this study was to report an adverse drug reaction in a child with sterile abscess formation following treatment with 2 different branded long-acting forms of GnRH agonists. CASE
SUMMARY: An otherwise healthy 8-year-old white female (weight, 40.7 kg; height, 140.1 cm) with documented CPP and no known drug allergies developed a sterile abscess at the site of the monthly intramuscular injection of 15 mg of leuprolide acetate. Because of this site reaction, a 50-mg histrelin acetate insert was placed in the patient's left arm. A similar reaction occurred 2 weeks after insert placement on 2 separate occasions in different arms. At the time of the removal of the second insert, Gram stain and swab culture of the purulent wound discharge were negative. The child was subsequently treated with intranasal nafarelin (800 ug twice daily) and tolerated it well. The Naranjo Adverse Drug Reaction Causality Score was 10 (definite, ≥9).
CONCLUSION: This report describes a case of sterile abscess formation definitely associated with 2 different forms of long-acting GnRH agonist treatment in a child.
Copyright © 2010 Excerpta Medica Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21194598     DOI: 10.1016/j.clinthera.2010.09.009

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  7 in total

1.  Central Precocious Puberty: Update on Diagnosis and Treatment.

Authors:  Melinda Chen; Erica A Eugster
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

2.  Central precocious puberty: treatment with triptorelin 11.25 mg.

Authors:  Elena Chiocca; Eleonora Dati; Giampiero I Baroncelli; Alessandra Cassio; Malgorzata Wasniewska; Fiorella Galluzzi; Silvia Einaudi; Marco Cappa; Gianni Russo; Silvano Bertelloni
Journal:  ScientificWorldJournal       Date:  2012-05-03

Review 3.  Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States.

Authors:  Jadranka Popovic; Mitchell E Geffner; Alan D Rogol; Lawrence A Silverman; Paul B Kaplowitz; Nelly Mauras; Philip Zeitler; Erica A Eugster; Karen O Klein
Journal:  Front Pediatr       Date:  2022-10-04       Impact factor: 3.569

Review 4.  Pros and cons of GnRHa treatment for early puberty in girls.

Authors:  Ruben H Willemsen; Daniela Elleri; Rachel M Williams; Ken K Ong; David B Dunger
Journal:  Nat Rev Endocrinol       Date:  2014-04-08       Impact factor: 43.330

5.  Long-acting atypical antipsychotics: characterization of the local tissue response.

Authors:  Sara Montminy Paquette; Had Dawit; Magali B Hickey; Elaine Merisko-Liversidge; Orn Almarsson; Daniel R Deaver
Journal:  Pharm Res       Date:  2014-02-21       Impact factor: 4.200

Review 6.  Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape.

Authors:  Alexey Fayzullin; Alesia Bakulina; Karen Mikaelyan; Anatoly Shekhter; Anna Guller
Journal:  Bioengineering (Basel)       Date:  2021-12-09

7.  Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.

Authors:  Karen O Klein; Analía Freire; Mirta Graciela Gryngarten; Gad B Kletter; Matthew Benson; Bradley S Miller; Tala S Dajani; Erica A Eugster; Nelly Mauras
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.